Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drug reduces chemotherapy-induced nausea and vomiting

15.10.2003


Two new studies now show that aprepitant – the first in a new class of drugs that interfere with the vomiting reflex – can substantially reduce chemotherapy-associated nausea and vomiting in cancer patients treated with cisplatin, a common type of chemotherapy. Results of both Journal of Clinical Oncology studies, early release articles published online October 14, formed the basis of the U.S. Food and Drug Administration’s approval of aprepitant in March 2003.



Aprepitant Combined with Standard Treatment for Nausea and Vomiting Helps Prevent These Symptoms Following Chemotherapy

The first study, led by Paul J. Hesketh, MD, at the Caritas St. Elizabeth’s Medical Center in Boston, found that adding aprepitant to the standard therapy to control nausea and vomiting could more effectively prevent these symptoms than the standard treatment alone. Nausea and vomiting were reduced both on the day that chemotherapy was given and, more importantly, in the several days that followed, when nausea and vomiting often occur.


"The nausea and vomiting that occurs 24 hours after receiving cisplatin is particularly problematic for patients, and aprepitant provided a substantial improvement," said Dr. Hesketh. "Aprepitant should change the standard of care for the treatment of chemotherapy-induced nausea and vomiting, especially for patients receiving chemotherapy drugs known to cause severe vomiting."

The international phase III study involved 520 patients with respiratory cancers, all of whom received ondansetron plus dexamethasone – the standard therapy to prevent nausea and vomiting. In addition, the patients were randomly assigned to receive oral aprepitant or a placebo. Patients kept diaries to document any nausea or vomiting that occurred on the day that chemotherapy was given and on the four days that followed, noting whether they needed additional medication to control these symptoms.

Researchers found that 26 percent of patients on the aprepitant regimen experienced nausea or vomiting, while nearly 48 percent of patients on the standard treatment experienced these side effects.

Results were particularly encouraging two to five days after the administration of chemotherapy, when standard treatments often fail. During this time period, 25 percent of patients on the aprepitant regimen reported nausea or vomiting, compared to 44 percent of those taking the standard drugs.

Aprepitant Added to Standard Therapy Protects Against Nausea and Vomiting Over Multiple Cycles of Chemotherapy

The second study, led by Ronald de Wit, MD, PhD, of the Rotterdam Cancer Institute in the Netherlands, found that the benefits of aprepitant extended over the course of multiple cycles of chemotherapy. Previous studies have shown that nausea and vomiting often become more severe over the course of several cycles of chemotherapy, and that standard therapy to control nausea and vomiting tends to become less effective as the number of chemotherapy cycles increases.

"This is a major clinical improvement in the ability to control nausea and vomiting – two of the most distressing side effects of chemotherapy," said Dr. de Wit. "The benefits experienced by patients taking aprepitant should be considered a major leap forward."

The international phase II clinical trial involved 164 cancer patients, all of whom were scheduled to receive up to six cycles of cisplatin. Recruited from 50 centers, including 21 in the United States, patients were randomly assigned to receive either oral aprepitant or a placebo, in addition to ondansetron and dexamethasone. Patients kept diaries identical to those in the previous study.

Researchers found that 64 percent of patients taking aprepitant plus standard therapy experienced no nausea or vomiting after the first cycle of cisplatin, compared to 49 percent of patients taking only the standard therapy. After six cycles of cisplatin therapy, 59 percent of patients who continued to take aprepitant along with the standard therapy reported no nausea or vomiting, compared to only 34 percent of those who received the standard therapy alone.

"This study shows that the benefits of aprepitant are not confined to the first cycle of chemotherapy and that this enhanced protection against nausea and vomiting can be sustained," said Dr. de Wit.


"The Oral NK1 Antagonist Aprepitant For the Prevention of Chemotherapy Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo Controlled Trial in Patients
Receiving High-Dose Cisplatin." Paul J. Hesketh, M.D., et al; Caritas St. Elizabeth’s Medical Center, Boston, Massachusetts.

"Addition of the Oral NK1 Antagonist Aprepitant (EMEND®) To Standard Antiemetics Provided Protection Against Nausea and Vomiting during Multiple Cycles of Cisplatin-Based Chemotherapy."
Ronald de Wit, M.D., et al; Rotterdam Cancer Institute, Rotterdam, The Netherlands.

The Journal of Clinical Oncology is the semi-monthly peer-reviewed journal of the American Society of Clinical Oncology (ASCO), the world’s leading professional society representing physicians who treat people with cancer.

Carrie Housman | EurekAlert!

More articles from Health and Medicine:

nachricht Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>